SUPN – Supernus Pharmaceuticals Inc

Float Short %

8.81

Margin Of Safety %

-16

Put/Call OI Ratio

0.99

EPS Next Q Diff

-0.17

EPS Last/This Y

2.47

EPS This/Next Y

-0.46

Price

49.05

Target Price

61.33

Analyst Recom

1.33

Performance Q

-3.1

Relative Volume

0.97

Beta

0.71

Ticker: SUPN

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	SUPN	51.59	0.77	7.00	2659
2025-12-29	SUPN	51.29	0.78	0.00	2666
2025-12-30	SUPN	49.82	0.78	0.00	2666
2025-12-31	SUPN	49.67	0.78	0.00	2666
2026-01-02	SUPN	49.45	0.78	0.00	2668
2026-01-05	SUPN	49.4	0.77	999.99	2669
2026-01-06	SUPN	49.28	0.78	0.25	2670
2026-01-07	SUPN	51.23	0.77	0.00	2669
2026-01-08	SUPN	51.16	0.53	0.00	3363
2026-01-09	SUPN	51.15	0.53	2.50	3376
2026-01-12	SUPN	51.33	0.53	0.01	3399
2026-01-13	SUPN	51.48	0.51	0.00	3489
2026-01-14	SUPN	51.8	0.51	0.00	3491
2026-01-15	SUPN	50.26	0.51	0.00	3486
2026-01-16	SUPN	50.04	0.52	1.00	3424
2026-01-20	SUPN	49.83	0.99	2.00	2348
2026-01-21	SUPN	49.49	0.99	0.00	2353
2026-01-22	SUPN	49.09	0.99	0.00	2354
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	SUPN	51.58	-20.4	-	3.81
2025-12-29	SUPN	51.26	-20.4	-	3.81
2025-12-30	SUPN	49.86	-20.4	-	3.81
2025-12-31	SUPN	49.66	-20.4	-	3.81
2026-01-02	SUPN	49.47	-20.4	-	3.81
2026-01-05	SUPN	49.41	-20.4	-	3.81
2026-01-06	SUPN	49.27	-20.4	-	3.81
2026-01-07	SUPN	51.23	-20.4	-	3.81
2026-01-08	SUPN	51.21	-20.4	-	3.81
2026-01-09	SUPN	51.15	-20.4	-	3.81
2026-01-12	SUPN	51.38	-28.0	-	3.81
2026-01-13	SUPN	51.43	-28.0	-	3.81
2026-01-14	SUPN	51.84	-28.0	-	3.81
2026-01-15	SUPN	50.26	-28.0	-	3.81
2026-01-16	SUPN	49.99	-28.0	-	3.81
2026-01-20	SUPN	49.83	-28.0	-	3.81
2026-01-21	SUPN	49.49	-28.0	-	3.81
2026-01-22	SUPN	49.05	-28.0	-	3.81
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	SUPN	-14.71	-3.20	8.84
2025-12-29	SUPN	-14.71	-3.20	8.84
2025-12-30	SUPN	-14.71	-3.20	8.84
2025-12-31	SUPN	-14.71	-3.20	8.84
2026-01-02	SUPN	-14.71	-3.20	8.84
2026-01-05	SUPN	-14.71	-3.20	8.84
2026-01-06	SUPN	-14.71	-3.20	8.84
2026-01-07	SUPN	-14.71	-3.20	8.84
2026-01-08	SUPN	-14.71	-3.20	8.84
2026-01-09	SUPN	-14.71	-3.20	8.84
2026-01-12	SUPN	-14.71	-3.09	8.84
2026-01-13	SUPN	-14.71	-3.09	8.05
2026-01-14	SUPN	-14.71	-3.09	8.05
2026-01-15	SUPN	-14.71	-3.09	8.05
2026-01-16	SUPN	-14.71	-3.09	8.05
2026-01-20	SUPN	-14.71	-2.90	8.06
2026-01-21	SUPN	-14.64	-2.90	8.06
2026-01-22	SUPN	-14.64	-2.90	8.81
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

0.61

Avg. EPS Est. Current Quarter

0.44

Avg. EPS Est. Next Quarter

0.45

Insider Transactions

-14.64

Institutional Transactions

-2.9

Beta

0.71

Average Sales Estimate Current Quarter

195

Average Sales Estimate Next Quarter

194

Fair Value

41.13

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

14.9

Max Drawdown 5-Year %

-45.9

Target Price

61.33

P/E

Forward P/E

14.12

PEG

1.82

P/S

4.13

P/B

2.67

P/Free Cash Flow

39.79

EPS

-0.34

Average EPS Est. Cur. Y

3.81

EPS Next Y. (Est.)

3.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2.8

Relative Volume

0.97

Return on Equity vs Sector %

-29.1

Return on Equity vs Industry %

-8.9

EPS 1 7Days Diff

EPS 1 30Days Diff

1.17

EBIT Estimation

Supernus Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 674

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

stock quote shares SUPN – Supernus Pharmaceuticals Inc Stock Price stock today

news today SUPN – Supernus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch SUPN – Supernus Pharmaceuticals Inc yahoo finance google finance

stock history SUPN – Supernus Pharmaceuticals Inc invest stock market

stock prices SUPN premarket after hours

ticker SUPN fair value insiders trading

OGI – OrganiGram Holdings Inc.

Float Short %

3.98

Margin Of Safety %

Put/Call OI Ratio

0.05

EPS Next Q Diff

0.2

EPS Last/This Y

EPS This/Next Y

0.04

Price

1.63

Target Price

2.47

Analyst Recom

1.5

Performance Q

-5.81

Relative Volume

0.54

Beta

1.6

Ticker: OGI

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	OGI	1.795	0.05	0.00	17648
2025-12-29	OGI	1.69	0.04	0.11	18746
2025-12-30	OGI	1.71	0.05	0.00	18786
2025-12-31	OGI	1.685	0.04	0.29	18863
2026-01-02	OGI	1.73	0.05	0.01	18926
2026-01-05	OGI	1.695	0.05	0.01	19021
2026-01-06	OGI	1.67	0.05	0.00	19044
2026-01-07	OGI	1.685	0.05	0.00	19202
2026-01-08	OGI	1.735	0.05	0.99	19283
2026-01-09	OGI	1.725	0.05	0.00	19317
2026-01-12	OGI	1.715	0.05	0.00	19379
2026-01-13	OGI	1.7	0.05	0.02	19457
2026-01-14	OGI	1.62	0.05	0.00	19511
2026-01-15	OGI	1.59	0.04	0.01	19461
2026-01-16	OGI	1.62	0.04	0.01	19479
2026-01-20	OGI	1.6	0.05	0.08	13032
2026-01-21	OGI	1.61	0.05	0.00	13031
2026-01-22	OGI	1.635	0.05	0.00	13031
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	OGI	1.79	-	-	0.01
2025-12-29	OGI	1.70	-	-	0.01
2025-12-30	OGI	1.71	-	-	0.01
2025-12-31	OGI	1.68	-	-	0.01
2026-01-02	OGI	1.74	-	-	0.01
2026-01-05	OGI	1.70	-	-	0.01
2026-01-06	OGI	1.67	-	-	0.01
2026-01-07	OGI	1.68	-	-	0.01
2026-01-08	OGI	1.74	-	-	0.01
2026-01-09	OGI	1.72	-	-	0.01
2026-01-12	OGI	1.72	-	-	0.01
2026-01-13	OGI	1.69	-	-	0.01
2026-01-14	OGI	1.62	-	-	0.01
2026-01-15	OGI	1.60	-	-	0.01
2026-01-16	OGI	1.62	-	-	0.01
2026-01-20	OGI	1.61	-	-	0.01
2026-01-21	OGI	1.61	-	-	0.01
2026-01-22	OGI	1.63	-	-	0.01
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	OGI	0.00	1.17	5.37
2025-12-29	OGI	0.00	1.18	5.37
2025-12-30	OGI	0.00	1.18	5.37
2025-12-31	OGI	0.00	1.18	5.37
2026-01-02	OGI	0.00	1.18	5.37
2026-01-05	OGI	0.00	1.17	5.37
2026-01-06	OGI	0.00	1.17	5.37
2026-01-07	OGI	0.00	1.17	5.37
2026-01-08	OGI	0.00	1.17	5.37
2026-01-09	OGI	0.00	1.17	5.37
2026-01-12	OGI	0.00	1.16	5.37
2026-01-13	OGI	0.00	1.16	3.99
2026-01-14	OGI	0.00	1.16	3.99
2026-01-15	OGI	0.00	1.16	3.99
2026-01-16	OGI	0.00	1.16	3.98
2026-01-20	OGI	0.00	1.08	3.98
2026-01-21	OGI	0.00	1.08	3.98
2026-01-22	OGI	0.00	1.08	3.98
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

-0.2

Avg. EPS Est. Current Quarter

-0.01

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

1.08

Beta

1.6

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

93.7

Max Drawdown 5-Year %

-96.3

Target Price

2.47

P/E

Forward P/E

30.99

PEG

P/S

1.18

P/B

0.87

P/Free Cash Flow

EPS

-0.16

Average EPS Est. Cur. Y

0.01

EPS Next Y. (Est.)

0.05

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-10.21

Relative Volume

0.54

Return on Equity vs Sector %

-34.3

Return on Equity vs Industry %

-14.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

Organigram Global Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 1139

Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers. It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online. Organigram Global Inc. was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025. The company is headquartered in Toronto, Canada.

stock quote shares OGI – OrganiGram Holdings Inc. Stock Price stock today

news today OGI – OrganiGram Holdings Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch OGI – OrganiGram Holdings Inc. yahoo finance google finance

stock history OGI – OrganiGram Holdings Inc. invest stock market

stock prices OGI premarket after hours

ticker OGI fair value insiders trading

MURA – Mural Oncology plc

Float Short %

2.66

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

2.04

Target Price

Analyst Recom

Performance Q

-1.45

Relative Volume

Beta

2.88

Ticker: MURA

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	MURA	2.04	N/A	N/A	0
2025-12-29	MURA	2.04	N/A	N/A	0
2025-12-30	MURA	2.04	N/A	N/A	0
2025-12-31	MURA	2.04	N/A	N/A	0
2026-01-02	MURA	2.04	N/A	N/A	0
2026-01-05	MURA	2.04	N/A	N/A	0
2026-01-06	MURA	2.04	N/A	N/A	0
2026-01-07	MURA	2.04	N/A	N/A	0
2026-01-08	MURA	2.04	N/A	N/A	0
2026-01-09	MURA	2.04	N/A	N/A	0
2026-01-12	MURA	2.04	N/A	N/A	0
2026-01-13	MURA	2.04	N/A	N/A	0
2026-01-14	MURA	2.04	N/A	N/A	0
2026-01-15	MURA	2.04	N/A	N/A	0
2026-01-16	MURA	2.04	N/A	N/A	0
2026-01-20	MURA	2.04	N/A	N/A	0
2026-01-21	MURA	2.04	N/A	N/A	0
2026-01-22	MURA	2.04	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

Last Quarter Act. EPS

-0.21

Avg. EPS Est. Current Quarter

-0.37

Avg. EPS Est. Next Quarter

Insider Transactions

-2.62

Institutional Transactions

-16.45

Beta

2.88

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

0.64

P/Free Cash Flow

EPS

-6.93

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

-0.39

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

-242.8

Return on Equity vs Industry %

-227.7

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Mural Oncology plc

Sector: Healthcare

Industry: Biotechnology

Employees: 116

Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland. As of December 4, 2025, Mural Oncology plc operates as a subsidiary of XOMA Royalty Corporation.

stock quote shares MURA – Mural Oncology plc Stock Price stock today

news today MURA – Mural Oncology plc stock forecast ,stock prediction 2023 2024 2025

marketwatch MURA – Mural Oncology plc yahoo finance google finance

stock history MURA – Mural Oncology plc invest stock market

stock prices MURA premarket after hours

ticker MURA fair value insiders trading

EVOK – Evoke Pharma Inc

Float Short %

0.73

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

2.56

Price

Target Price

Analyst Recom

Performance Q

116.11

Relative Volume

Beta

-0.1

Ticker: EVOK

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	EVOK	11	N/A	N/A	0
2025-12-29	EVOK	11	N/A	N/A	0
2025-12-30	EVOK	11	N/A	N/A	0
2025-12-31	EVOK	11	N/A	N/A	0
2026-01-02	EVOK	11	N/A	N/A	0
2026-01-05	EVOK	11	N/A	N/A	0
2026-01-06	EVOK	11	N/A	N/A	0
2026-01-07	EVOK	11	N/A	N/A	0
2026-01-08	EVOK	11	N/A	N/A	0
2026-01-09	EVOK	11	N/A	N/A	0
2026-01-12	EVOK	11	N/A	N/A	0
2026-01-13	EVOK	11	N/A	N/A	0
2026-01-14	EVOK	11	N/A	N/A	0
2026-01-15	EVOK	11	N/A	N/A	0
2026-01-16	EVOK	11	N/A	N/A	0
2026-01-20	EVOK	11	N/A	N/A	0
2026-01-21	EVOK	11	N/A	N/A	0
2026-01-22	EVOK	11	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

1 item of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	EVOK	-3.69	0	0.73
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

1 item 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.3

Avg. EPS Est. Next Quarter

Insider Transactions

-3.69

Institutional Transactions

Beta

-0.1

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

98.4

Max Drawdown 5-Year %

-99.7

Target Price

P/E

Forward P/E

PEG

P/S

1.31

P/B

5.64

P/Free Cash Flow

EPS

-2.38

Average EPS Est. Cur. Y

-1.88

EPS Next Y. (Est.)

0.68

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-36.23

Relative Volume

Return on Equity vs Sector %

-166.4

Return on Equity vs Industry %

-162.7

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.08

EBIT Estimation

Evoke Pharma, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 3

Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California. As of December 15, 2025, Evoke Pharma, Inc. operates as a subsidiary of QOL Medical, LLC.

stock quote shares EVOK – Evoke Pharma Inc Stock Price stock today

news today EVOK – Evoke Pharma Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch EVOK – Evoke Pharma Inc yahoo finance google finance

stock history EVOK – Evoke Pharma Inc invest stock market

stock prices EVOK premarket after hours

ticker EVOK fair value insiders trading

AMPH – Amphastar Pharmaceuticals Inc

Float Short %

11.99

Margin Of Safety %

Put/Call OI Ratio

0.11

EPS Next Q Diff

-0.04

EPS Last/This Y

0.09

EPS This/Next Y

0.18

Price

26.14

Target Price

31.57

Analyst Recom

2.14

Performance Q

7.77

Relative Volume

0.58

Beta

0.88

Ticker: AMPH

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	AMPH	27.13	0.24	0.00	549
2025-12-29	AMPH	26.81	0.24	0.05	554
2025-12-30	AMPH	27.03	0.23	0.00	575
2025-12-31	AMPH	26.78	0.23	0.00	579
2026-01-02	AMPH	26.47	0.23	0.00	580
2026-01-05	AMPH	26.73	0.23	0.00	581
2026-01-06	AMPH	27.64	0.23	0.00	581
2026-01-07	AMPH	27.34	0.23	0.00	581
2026-01-08	AMPH	27.72	0.22	0.00	587
2026-01-09	AMPH	27.74	0.22	0.00	587
2026-01-12	AMPH	29.4	0.22	0.20	599
2026-01-13	AMPH	28.93	0.22	0.27	610
2026-01-14	AMPH	27.77	0.22	0.00	629
2026-01-15	AMPH	25.98	0.20	0.06	674
2026-01-16	AMPH	26.07	0.12	0.00	636
2026-01-20	AMPH	25.96	0.11	0.14	625
2026-01-21	AMPH	26.19	0.12	0.02	637
2026-01-22	AMPH	26.15	0.11	0.00	679
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	AMPH	27.14	0.2	-	3.38
2025-12-29	AMPH	26.78	0.2	-	3.38
2025-12-30	AMPH	27.02	0.2	-	3.38
2025-12-31	AMPH	26.81	0.2	-	3.38
2026-01-02	AMPH	26.48	0.2	-	3.38
2026-01-05	AMPH	26.74	0.2	-	3.38
2026-01-06	AMPH	27.61	0.2	-	3.38
2026-01-07	AMPH	27.35	0.2	-	3.38
2026-01-08	AMPH	27.74	0.2	-	3.38
2026-01-09	AMPH	27.73	0.2	-	3.38
2026-01-12	AMPH	29.41	0.2	-	3.38
2026-01-13	AMPH	28.93	0.2	-	3.38
2026-01-14	AMPH	27.76	0.2	-	3.38
2026-01-15	AMPH	26.00	0.2	-	3.38
2026-01-16	AMPH	26.07	0.2	-	3.38
2026-01-20	AMPH	25.96	0.2	-	3.38
2026-01-21	AMPH	26.22	0.2	-	3.38
2026-01-22	AMPH	26.14	0.2	-	3.38
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	AMPH	-0.29	0.01	11.98
2025-12-29	AMPH	-0.29	-0.01	11.98
2025-12-30	AMPH	-0.29	-0.01	11.98
2025-12-31	AMPH	-0.29	-0.01	11.98
2026-01-02	AMPH	-0.29	-0.01	11.98
2026-01-05	AMPH	-0.29	-0.01	11.98
2026-01-06	AMPH	-0.29	-0.01	11.98
2026-01-07	AMPH	-0.29	-0.01	11.98
2026-01-08	AMPH	-0.29	-0.01	11.98
2026-01-09	AMPH	-0.29	-0.01	11.98
2026-01-12	AMPH	-0.29	-0.10	11.98
2026-01-13	AMPH	-0.29	-0.10	12.33
2026-01-14	AMPH	-0.29	-0.10	12.33
2026-01-15	AMPH	-0.29	-0.10	12.33
2026-01-16	AMPH	-0.29	-0.10	12.33
2026-01-20	AMPH	-0.29	-0.01	12.33
2026-01-21	AMPH	-0.29	-0.01	12.33
2026-01-22	AMPH	-0.29	-0.01	11.99
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

0.83

Avg. EPS Est. Current Quarter

0.92

Avg. EPS Est. Next Quarter

0.79

Insider Transactions

-0.29

Institutional Transactions

-0.01

Beta

0.88

Average Sales Estimate Current Quarter

190

Average Sales Estimate Next Quarter

173

Fair Value

33.23

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

61.4

Max Drawdown 5-Year %

-68.3

Target Price

31.57

P/E

11.59

Forward P/E

7.18

PEG

P/S

1.66

P/B

1.56

P/Free Cash Flow

10.61

EPS

2.26

Average EPS Est. Cur. Y

3.38

EPS Next Y. (Est.)

3.56

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

15.43

Relative Volume

0.58

Return on Equity vs Sector %

-12.9

Return on Equity vs Industry %

7.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

Amphastar Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 2028

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

stock quote shares AMPH – Amphastar Pharmaceuticals Inc Stock Price stock today

news today AMPH – Amphastar Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch AMPH – Amphastar Pharmaceuticals Inc yahoo finance google finance

stock history AMPH – Amphastar Pharmaceuticals Inc invest stock market

stock prices AMPH premarket after hours

ticker AMPH fair value insiders trading

ALKS – Alkermes plc

Float Short %

14.18

Margin Of Safety %

-19

Put/Call OI Ratio

1.19

EPS Next Q Diff

-0.21

EPS Last/This Y

-0.29

EPS This/Next Y

0.01

Price

33.94

Target Price

43.69

Analyst Recom

1.44

Performance Q

7.95

Relative Volume

1.17

Beta

0.48

Ticker: ALKS

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	ALKS	28.48	2.75	1.05	10948
2025-12-29	ALKS	28	2.71	0.11	11046
2025-12-30	ALKS	27.79	2.63	1.24	11154
2025-12-31	ALKS	27.98	2.65	3.71	11214
2026-01-02	ALKS	28.25	2.65	77.33	11248
2026-01-05	ALKS	27.98	2.32	21.92	10243
2026-01-06	ALKS	28.78	2.06	0.42	9529
2026-01-07	ALKS	29.37	2.04	0.29	9549
2026-01-08	ALKS	29.6	2.03	0.49	9574
2026-01-09	ALKS	29.65	1.42	0.22	12620
2026-01-12	ALKS	29.61	1.43	0.39	12626
2026-01-13	ALKS	29.29	1.43	0.98	12642
2026-01-14	ALKS	30.7	1.36	0.23	14647
2026-01-15	ALKS	31.22	1.33	0.13	14858
2026-01-16	ALKS	31.65	1.30	0.01	15029
2026-01-20	ALKS	31.76	1.30	0.10	7312
2026-01-21	ALKS	33.85	1.19	0.15	7663
2026-01-22	ALKS	33.96	1.19	1.16	7676
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	ALKS	28.48	-61.7	-79.7	1.93
2025-12-29	ALKS	28.01	-61.7	-86.2	1.93
2025-12-30	ALKS	27.81	-61.7	-82.2	1.93
2025-12-31	ALKS	27.97	-61.7	-76.7	1.93
2026-01-02	ALKS	28.25	-61.7	-75.0	1.93
2026-01-05	ALKS	27.98	-61.7	-83.3	1.93
2026-01-06	ALKS	28.78	-61.7	-67.4	1.93
2026-01-07	ALKS	29.38	-61.7	-70.4	1.93
2026-01-08	ALKS	29.61	-61.7	-75.6	1.93
2026-01-09	ALKS	29.66	-61.7	-78.3	1.93
2026-01-12	ALKS	29.61	-62.8	-79.8	1.93
2026-01-13	ALKS	29.19	-62.8	-85.2	1.93
2026-01-14	ALKS	30.65	-61.3	-57.7	1.93
2026-01-15	ALKS	31.23	-61.3	-71.4	1.93
2026-01-16	ALKS	31.62	-61.3	-73.9	1.93
2026-01-20	ALKS	31.75	-59.4	-77.5	1.93
2026-01-21	ALKS	33.85	-59.4	-52.2	1.93
2026-01-22	ALKS	33.94	-60.0	-78.0	1.93
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	ALKS	-0.69	1.19	12.41
2025-12-29	ALKS	-0.69	1.19	12.41
2025-12-30	ALKS	-0.69	1.19	12.41
2025-12-31	ALKS	-0.69	1.19	12.41
2026-01-02	ALKS	-0.80	1.19	12.41
2026-01-05	ALKS	-0.80	1.15	12.41
2026-01-06	ALKS	-0.80	1.15	12.41
2026-01-07	ALKS	-0.80	1.15	12.41
2026-01-08	ALKS	-0.80	1.15	12.41
2026-01-09	ALKS	-0.93	1.15	12.41
2026-01-12	ALKS	-0.94	1.17	12.41
2026-01-13	ALKS	-0.93	1.17	13.53
2026-01-14	ALKS	-0.93	1.17	13.53
2026-01-15	ALKS	-0.93	1.17	13.53
2026-01-16	ALKS	-0.93	1.17	13.53
2026-01-20	ALKS	-0.93	1.26	13.53
2026-01-21	ALKS	-0.93	1.26	13.53
2026-01-22	ALKS	-0.93	1.26	14.18
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

0.49

Avg. EPS Est. Current Quarter

0.4

Avg. EPS Est. Next Quarter

0.28

Insider Transactions

-0.93

Institutional Transactions

1.26

Beta

0.48

Average Sales Estimate Current Quarter

378

Average Sales Estimate Next Quarter

367

Fair Value

27.43

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

6.9

Max Drawdown 5-Year %

-33.2

Target Price

43.69

P/E

16.8

Forward P/E

19.68

PEG

P/S

3.68

P/B

3.23

P/Free Cash Flow

11.42

EPS

2.02

Average EPS Est. Cur. Y

1.93

EPS Next Y. (Est.)

1.93

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

22.27

Relative Volume

1.17

Return on Equity vs Sector %

-7.7

Return on Equity vs Industry %

12.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.03

EBIT Estimation

-78

Alkermes plc

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 1800

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

stock quote shares ALKS – Alkermes plc Stock Price stock today

news today ALKS – Alkermes plc stock forecast ,stock prediction 2023 2024 2025

marketwatch ALKS – Alkermes plc yahoo finance google finance

stock history ALKS – Alkermes plc invest stock market

stock prices ALKS premarket after hours

ticker ALKS fair value insiders trading

No more stocks to show

SUPN – Supernus Pharmaceuticals Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: SUPN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

OGI – OrganiGram Holdings Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: OGI

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y